April 19, 2021

Lonnie Listonsmith

Experienced Health Expert

AstraZeneca

1 min read

Photographer: Veejay Villafranca/Bloomberg

To judge by the headlines, you’d think the most critical immunization issue facing the world is the safety and hesitancy concerns over the AstraZeneca Plc and Johnson & Johnson vaccines.

That debate is genuinely important. Still, it shouldn’t distract from the biggest challenge the world will face over the coming months: the grossly unequal distribution of vaccines between rich and poor countries.

The development and ramp-up of preventive medicine for the coronavirus is a testament to the innovative power of the modern global economy. Counting only drugs that are

Read More
1 min read

CANBERRA, Australia — Australian authorities have identified a second case of a rare blot clot likely linked to the AstraZeneca coronavirus vaccine.

Officials said Tuesday the woman is in her 40s and is in a stable condition. A 44-year-old man developed the same condition following an AstraZeneca injection March 22.

Australia has administered 700,000 doses of the AstraZeneca vaccine since early March. That equates to a clotting frequency of 1-in-350,000 cases. British authorities say the risk of such blood clots has been 1-in-250,000 in that country.

Australia had planned to rely on Australian-manufactured AstraZeneca for delivering at least one dose

Read More
1 min read

CANBERRA, Australia — Australian authorities have identified a second case of a rare blot clot likely linked to the AstraZeneca coronavirus vaccine.

Officials said Tuesday the woman is in her 40s and is in a stable condition. A 44-year-old man developed the same condition following an AstraZeneca injection March 22.

Australia has administered 700,000 doses of the AstraZeneca vaccine since early March. That equates to a clotting frequency of 1-in-350,000 cases. British authorities say the risk of such blood clots has been 1-in-250,000 in that country.

Australia had planned to rely on Australian-manufactured AstraZeneca for delivering at least one dose

Read More
1 min read

Welcome to Monday’s Overnight Health Care. If you need more incentive to get vaccinated, Krispy Kreme has you covered. 

If you have any tips, email us at [email protected]and [email protected], and follow us on Twitter at @NateWeixel and @PeterSullivan4

Today: The CDC director is warning that another COVID surge is avoidable, AstraZeneca published initial U.S. results for its vaccine, and more states are opening vaccine eligibility.

We’ll start with a warning:

Don’t get careless: CDC director warns of ‘avoidable surge’ of COVID-19 amid relaxing precautions

Centers for Disease Control and Prevention (CDC) Director Rochelle WalenskyRochelle WalenskyThe Hill’s Morning Report

Read More
1 min read
Credit…Alessandro Grassani for The New York Times

Federal health officials said early Tuesday that results from a U.S. trial of AstraZeneca’s Covid-19 vaccine may have relied on “outdated information” that “may have provided an incomplete view of the efficacy data,” casting doubt on an announcement on Monday that had been seen as good news for the British-Swedish company as well as the global vaccination drive.

In a highly unusual statement released after midnight, the National Institute of Allergy and Infectious Diseases said that the

Read More
1 min read

South Africa suspended the start of its AstraZeneca inoculation program over concerns the shot doesn’t work nearly as well against the new variant of the coronavirus first discovered in the country. World Health Organization experts were due to meet Monday to discuss the vaccine.

A trial showed the vaccine, developed by AstraZeneca and Oxford University, provides only “minimal” protection against mild to moderate COVID-19 infection caused specifically by the variant that has swept through South Africa. The strain, believed to be more easily transmitted but not to cause significantly more serious illness, has also been detected in the U.S.,

Read More
lonnielistonsmith.net© All rights reserved. | Newsphere by AF themes.